

Application No. 09/847,946  
Amldt dated February 10, 2005  
Reply to Office Action of August 13, 2004

2

Amendments to the Specification:

Please replace the insertion on page 1, with the following amended paragraph:

"REFERENCE TO RELATED APPLICATIONS"

This application is a national phase application under 35 U.S.C. 371 of PCT/CA99/00292 filed April 7, 1999, which claims priority from US Patent Application No. 09/055,765 filed April 7, 1998 (now US Patent No. 6,344,202)."

Please replace the paragraph beginning at page 8, line 1, with the following rewritten paragraph:

"Figures 10A to 10F show Figure 10 shows a comparison of the amino acid sequence of MOMP sequences (SEQ ID NOS: 1 to 15) from a variety of serovars of *C. trachomatis*. Residues which are identical to serovar E MOMP are represented by dots. The four VDs (VDI to VDIV) and the conserved cysteines are boxed by solid line. The conserved position where one cysteine is located in all *C. trachomatis* and *C. pneumoniae* MOMP sequences, but where one serine is located in GPIC and Mn MOMP, is boxed by a broken line. Numbers above boxes denote amino acid residues of serovar E MOMP only."

Please replace the paragraph beginning at page 8, line 22, with the following rewritten paragraph:

"Any convenient plasmid vector may be used for the MOMP gene fragment, such as pcDNA3, a eukaryotic  $\beta$ -selectable expression vector (Invitrogen, San Diego, CA, USA), containing a *cytomegalovirus* *cytomegalovirus* promoter. The MOMP gene fragment may be inserted in the vector in any convenient manner. The gene fragments may be amplified from *Chlamydia trachomatis* genomic DNA by PCR using suitable primers and the PCR product cloned into the vector. The MOMP gene-carrying plasmid may be transferred, such as by electroporation, into *E. coli* for replication therein. Plasmids may be extracted from the *E. coli* in any convenient manner."

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

(Application Serial No.) \_\_\_\_\_ (Filing Date) \_\_\_\_\_

(Application Serial No.) \_\_\_\_\_ (Filing Date) \_\_\_\_\_

(Application Serial No.) \_\_\_\_\_ (Filing Date) \_\_\_\_\_

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

09/055,765 (Application Serial No.)	April 7, 1998 (Filing Date)	Pending (Status) (patented, pending, abandoned)
PCT/CA99/00292 (Application Serial No.)	April 7, 1999 (Filing Date)	(Status) (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.